The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders

A single-center, retrospective chart review evaluating outpatient code status documentation in the EPIC electronic medical record for patients with advanced solid tumor cancer.

(2017) John M. Horton et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteasome inhibitors

(2015) Beverly A. Teicher et al.   BIOCHEMICAL PHARMACOLOGY

Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study

(2015) Ahmad-Samer Al-Homsi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

(2015) John Koreth et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study

(2015) Terzah M. Horton et al.   BRITISH JOURNAL OF HAEMATOLOGY

CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341

(2015) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma

(2015) Haruhito Totani et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines

(2015) S. Junk et al.   KLINISCHE PADIATRIE

Bortezomib for Refractory Autoimmunity in Pediatrics

(2014) Pooja Khandelwal et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of chronic graft-versus-host disease with bortezomib

(2014) C.-C. S. Pai et al.   BLOOD

Bortezomib treatment causes long-term testicular dysfunction in young male mice

(2014) Mi Hou et al.   Molecular Cancer

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

(2014) Terzah M. Horton et al.   PEDIATRIC BLOOD & CANCER

Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature

(2014) Sakura Hosoba et al.   TRANSFUSION

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

(2014) Massimo Offidani et al.   OncoTargets and Therapy

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

New orally active proteasome inhibitors in multiple myeloma

(2013) Alessandro Allegra et al.   LEUKEMIA RESEARCH

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

(2012) Eyal C. Attar et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside

(2012) A. R. Mato et al.   ONCOLOGIST

Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone Growth in Young Mice

(2012) Emma Eriksson et al.   PLoS One

Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience

(2012) Eva Moran et al.   SEMINARS IN HEMATOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection

(2011) J. Waiser et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide

(2010) Pongwut Danchaivijitr et al.   AMERICAN JOURNAL OF HEMATOLOGY

Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib

(2010) K. R. Carson et al.   BLOOD

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium

(2010) Yoav Messinger et al.   PEDIATRIC BLOOD & CANCER

The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation

(2010) Stuart M. Flechner et al.   TRANSPLANTATION

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population

(2009) B. Blanco et al.   HAEMATOLOGICA

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

(2008) E. C. Attar et al.   CLINICAL CANCER RESEARCH

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

(2008) J. El-Cheikh et al.   HAEMATOLOGICA

Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

(2008) Matthew J. Everly et al.   TRANSPLANTATION

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER